Creating defined live microbial treatments for infections and inflammation
Official title: Manufacture of defined live microbial therapeutics for infectious and inflammatory disease
Funded at Icahn School of Medicine at Mount Sinai · NIH-11024873 · Data updated 2026-11-12
This study is testing a new treatment made from specially grown bacteria to help people with recurring Clostridioides difficile infections, aiming to see if it's more effective and safer than traditional stool transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $671,511 |
| NIH project number | 1R01DK141891-01 |
| Project ID | NIH-11024873 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients experiencing recurrent Clostridioides difficile infections who have not responded to standard treatments.
✕Less likely to help
Patients with non-infectious gastrointestinal disorders or those not affected by Clostridioides difficile infections may not benefit from this research.
What this research studies
This research focuses on developing defined live biotherapeutic products (LBPs) to treat recurrent Clostridioides difficile infections. Unlike traditional fecal-based therapies, which can vary in safety and require stool donations, this approach uses in vitro manufactured bacterial strains that can be produced at scale. The study aims to compare the effectiveness of these defined LBPs against fecal transplants in a clinical trial, providing a more consistent and safer treatment option for patients. By utilizing specific bacterial strains known for their therapeutic benefits, the research seeks to enhance patient outcomes in managing infections.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients suffering from recurrent Clostridioides difficile infections.
How similar studies have gone: Previous research has shown promise in using defined microbial therapeutics, indicating a potential for success with this novel approach.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Faith, Jeremiah James — Icahn School of Medicine at Mount Sinai
- Study coordinator: Faith, Jeremiah James
Related research
Other NIH-funded projects on the same topics.
-
Glutathionylated products from lipid oxidation in eye disease
This project studies how lipid-oxidation products in the eye might drive age-related macular degeneration and related conditions, by looking at molecules that behave like inflammatory signals.
-
Inflammation risks in clonal hematopoiesis and cancer
This grant studies how clonal hematopoiesis may drive inflammatory diseases and helps predict who is at risk so doctors can prevent complications in people with blood cancers.
-
IgE responses to alpha-gal and how they relate to allergic disease
This project studies why some people develop allergic reactions to mammal products due to alpha-gal and what this means for diagnosing and managing the condition.
-
Alpha‑gal allergy: delayed reactions to red meat and mammal‑derived products
Researchers are looking at why some adults get delayed allergic reactions hours after eating mammal products (alpha‑gal) and how to better diagnose and manage them.
-
A signaling switch that keeps inflammation in check in lupus-like disease
Researchers study how a signaling module in immune cells controls inflammation linked to lupus by examining proteins that turn inflammation on and off.
-
Gut bacteria and steroid hormones in inflammatory bowel disease
A study in people and mice looks at how gut bacteria may change steroids that reduce inflammation in inflammatory bowel disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.